Eliminating copays for preventive medications prescribed for post-heart attack patients can significantly improve medication adherence for all patients, according to a study published in Health Affairs.
Dr Shrank
Eliminating copays for preventive medications prescribed for post-heart attack patients can significantly improve medication adherence for all patients, according to a study published in Health Affairs.
In addition, providing full drug coverage reduced healthcare spending by 70% among self-identified, non-white patients and also improved health outcomes for these patients.
This secondary analysis evaluated data from the randomized Myocardial Infarction Free Rx Event and Economic Evaluation MI FREEE) trial to see whether providing full coverage for post-MI medications had differential effects based on race and ethnicity. Researchers from CVS Caremark and Brigham and Women’s Hospital analyzed data from the MI FREEE trial conducted by Aetna and Brigham and Women’s Hospital and previously published in 2011.
“Racial and ethnic disparities in cardiovascular care have been widely documented in the peer-reviewed literature and persist despite overall improvements in cardiovascular mortality and risk factor control. This study suggests eliminating copays may be an effective strategy in improving adherence and reducing disparities in cardiovascular care in non-white patients,” said William Shrank, MD, senior vice president and chief scientific officer of CVS Caremark.
There have been a lot of studies demonstrating that disparities in care exist, according to Dr Shank. “This study shows us a straightforward way to reduce those disparities and improve health outcomes. We should note that the value based insurance design [VBID] approach of eliminating copayments for maintenance medications after a heart attack is actually a relatively simple, low-risk change that should be considered for broader usage,” he said.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More